Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 9k
23 January 2020
E-000380/2020
Question for written answer
to the Commission
Rule 138
Bartosz Arłukowicz
 Subject: Medicines shortages

Over the last few years, patients in a number of Member States have experienced medicines shortages. In many of those places, unfortunately, the shortages affect medicines for thyroid disease, diabetes and even cancer. An effective health policy cannot be achieved if the medicines supply chain is disrupted.

The issue seems to lie, at least partly, in the intersection between health policy and economic policy. In particular, over-reliance on imports of active substances from third countries – covering 80% of demand in some cases – has brought to light policy flaws, including at EU level. In connection with the above, can the Commission say:

Has it undertaken studies into the EU’s medicine shortages, and in particular the reasons behind those shortages?

Is it planning to give the European Medicines Agency funds to help it monitor the situation on the medicines market more closely and warn Member States in advance of any possible supply restrictions?

Is it in regular contact with Member State partners, and is it gathering the information needed to create a system that could prevent medicines shortages in future?

Original language of question: PL
Last updated: 6 February 2020Legal notice - Privacy policy